Menin Inhibitors in Relapsed/Refractory AML: Optimizing Selection, Safety, and Access

Meeting Objectives:

• • Discuss molecular testing workflows for KMT2A rearrangements and NPM1 mutations to identify patients with relapsed/refractory AML who may be eligible for menin inhibitor therapy
  • Compare label-specific recommendations between revumenib and ziftomenib regarding differentiation syndrome, QTc monitoring, and drug interactions to build effective monitoring and counseling protocols.
  • Implement strategies for starting and maintaining therapy on menin inhibitors across sites of care, including prior authorization and financial navigations.